Search PubMed⌕ Search

Biomedical subjects

A Gottlieb

Publications and source records attributed to A Gottlieb.

At least 91 records · Page 5Linked to original sources
PubMed1986

Exostosis as a cause of spinal cord compression.

A patient harboring multiple hereditary exostoses with a long-lasting tetraparesis owing to intraspinal osteochondroma is described. The results of surgical treatment were poor in contrast to the results achieved by other previous authors performing decompression of the spinal cord. The related literature is briefly reviewed and conclusions are drawn in favor of computed tomographic examination of the spine of patients with vertebral complaints.

Adult↗
PubMed1986

Cefuroxime axetil for treatment of uncomplicated gonorrhea.

Oral cefuroxime axetil (1 g) plus probenecid cured 29 of 30 urethral and 6 of 6 rectal gonococcal infections in men; alone the drug cured 22 of 23 urethral and 4 of 6 rectal infections. No toxicity was observed. Cefuroxime axetil alone is effective for urethral gonorrhea in males; rectal gonorrhea probably requires additional probenecid.

Adolescent↗
PubMed1986

Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B.

A randomized clinical trial of combination chemotherapy for patients who relapsed following primary radiation therapy for Hodgkin's disease was conducted from 1975 to 1981 by the Cancer and Leukemia Group B (CALGB). One hundred thirteen patients were prospectively randomized to receive 12 cycles of either CVPP (CCNU, vinblastine, procarbazine, and prednisone), ABOS (bleomycin, vincristine [Oncovin; Lilly, Indianapolis], doxorubicin [Adriamycin, Adria Laboratories, Columbus, Ohio], and streptozotocin), or alternating cycles of CVPP and ABOS. The median length of observation for patients in this report is 4 years. Toxicities of the three treatment programs were primarily hematologic. Frequencies of complete response were 72% for CVPP, 70% for ABOS, and 82% for CVPP/ABOS (P = .37). Females and patients who had nodular sclerosing disease at initial diagnosis had significantly higher complete response rates. The 5-year disease-free survival for the complete responders was 55%; the 5-year overall survival was 60%. There were no significant differences among the treatments on disease-free survival (P = .78) or overall survival (P = .18). Age under 40 years was the only significant positive prognostic factor for disease-free survival (P = .095) and overall survival (P = .003). This study demonstrates no statistically significant advantage for alternating cycles of combination chemotherapy in affecting complete response frequency, disease-free survival, or overall survival as compared with therapy with CVPP or ABOS alone. However, the power to detect differences in these outcome parameters is somewhat limited by the sample sizes.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1985

Long-term prognosis of subarachnoid hemorrhages of unknown etiology.

Forty-nine patients who suffered a spontaneous subarachnoid hemorrhage (SAH), and in whom panangiography did not show the cause of the bleeding, were evaluated after a long follow-up (median 8 years). No relationship was found between outcome and antifibrinolytic treatment or blood pressure level. Angiography was repeated in cases with spasm or after rebleeding: one aneurysm was found (7%). The authors suggest that angiography should be repeated in these circumstances. The early mortality was 2%. Late functional capacity was normal in 94% of the patients. No particular restrictions should therefore be recommended.

Adult↗
PubMed1985

Effectiveness of aztreonam for the treatment of gonorrhea.

Aztreonam, 1 g intramuscularly, was compared with spectinomycin, 2 g intramuscularly, for uncomplicated gonorrhea. There were no failures with either drug. For aztreonam, there were 26 urethral, 3 rectal, and 3 endocervical sites that were infected. Aztreonam in a single dose of 1 g intramuscularly is satisfactory therapy for uncomplicated urethral gonorrhea in men and may be effective for rectal and endocervical infection as well.

Adolescent↗
PubMed1985

Placement dilemma.

Explore the source record for details and available documents.

Office Management↗
PubMed1984

[The role of open neurosurgery in the treatment of cancer pain].

After a brief foreword on the indication of open surgery in the treatment of neoplastic pain those procedures are detailed which are more effective and widely used: Posterior Rhizotomy, Cordotomy, Mediolongitudinal Mielotomy and Bulbar trigeminal tractotomy. Of each procedure main technical features, indications and complications are detailed. It is concluded that these techniques are still very useful in management of severe cancer pain.

Cordotomy↗
PubMed1984

Inhibition of DNA synthesis by cytosine arabinoside: relation to response of acute non-lymphocytic leukemia to remission induction therapy and to stage of the disease.

The sensitivity of leukemic marrow cell DNA synthesis to cytosine arabinoside (araC) exposure in vitro was studied in specimens obtained from patients with acute non-lymphocytic leukemia. Cells from patients who had been treated with araC in the past were more likely to be resistant to the effect of araC on DNA synthesis than cells obtained from patients who had not been so-treated previously. Resistance to the effects of araC on DNA synthesis was associated with the failure of high-dose araC therapy to induce remissions in relapsed patients, whereas remission induction failure in previously untreated patients was not associated with araC resistance.

Acute Disease↗
PubMed1983

Assessment of the quality of life in long-term survivors after definitive radiotherapy.

An interview questionnaire was developed to assess quality of life both in objective and subjective terms in cancer patients. Standardized measures were employed and allowed for comparison with a national baseline. Three hundred thirty-nine patients who were alive without evidence of disease 3 or more years following initial treatment were interviewed. There was no difference in terms of educational level, marital status, or satisfaction with local government, family, job, friends, community, health, recreation, or activities when compared to the age-adjusted national baseline. The patients were more satisfied with region, self, and life as a whole. There was no evidence of a diminished quality of life in these patients.

Adolescent↗
PubMed1983

Inhibition of bacterial adherence to hydrocarbons and epithelial cells by emulsan.

Acinetobacter calcoaceticus RAG-1 and BD413, as well as Streptococcus pyogenes M-5, adhered to octane. Adherence was inhibited by emulsan (100 micrograms/ml), the polymeric emulsifying agent produced by A. calcoaceticus RAG-1. Emulsan also inhibited adherence of S. pyogenes and RAG-1 to buccal epithelial cells. The mean values of bound S. pyogenes per epithelial cell were 57.2 and 20.7 for the control and emulsan-containing suspensions, respectively; mean values of bound RAG-1 per epithelial cell were 221 for the control and 40 for the suspension containing 100 micrograms of emulsan per ml. Desorption of previously bound RAG-1 from epithelial cells by emulsan was concentration dependent: a maximum of 80% desorption was obtained with 200 micrograms of emulsan per ml. The data showing that emulsan desorbed 70% of the indigenous bacterial flora from buccal epithelial cells suggest that hydrophobic interactions mediate not only the in vitro adherence of laboratory strains to epithelial cells, but actually govern the adherence of the majority of the bacteria that colonize this surface. The advantages of using emulsan as an antiadherence agent include its chemical purity, stability, and polymeric nature.

Acinetobacter↗
PubMed1983

[Mutagenicity of 3 organic fractions of atmospheric dust and gas chromatographic analysis of the basic fraction].

Suspended particulate matter (PM) with a Dae less than 0.4 micron was collected from July 1981 till January 1982. The ether/benzene soluble extract (EEOM) and the acidic, basic and neutral fractions were determined and investigated for their mutagenic activities in the Ames bioassay. In addition particles (Dae) less than 10.2 micron derived in January were investigated. Five compounds of the basic fraction were determined by gaschromatography. The following results were obtained: Suspended particulate matter (Dae less than 0.4 micron) and the ether/benzene extract increase from July to January. The lowest rates occur in July (PM: 16.9 micron/m3) and August (EEOM: 3.0 micrograms/m3), the highest in January (PM: 48.9 micrograms/m3, EEOM: 10.5 micrograms/m3). The ether/benzene soluble portion of the suspended particulate matter increases from the average rate of 16.3% (July-September) to 22.7% (November-January). The neutral fraction amounts to 44.9%, the acidic fraction to 27.3% and the basic fraction to 3.5% of the organic matter (on an average). In experiments with metabolic activation 99% of the total mutagenicity during the period of July till September can be demonstrated by summing up the mutagenicity of the three fractions on the other hand only 59.7% from November till January. The EEOMs derived from winter exhibit without metabolic activation (250 micrograms/plate) distinctively higher numbers of revertants than the single fractions. Dose-response curves of extracts derived from back-up filters (Dae less than 0.4 micron) in January show that the acidic fraction has a slightly higher mutagenic activity than the neutral fraction (mean values of tests with and without S9-mix). The basic fraction shows no mutagenicity without S9-mix, with activation the mutagenic activity is lower than that of the other fractions. Mutagenicity expressed as rev./m3 air shows, that the neutral fraction is most efficient. The number of revertants per plate reveals-in relation to the particle size-different results concerning the three fractions (January).

Acridines↗
PubMed1982

Effect of methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin's disease.

One-hundred-ninety-six patients with Stage III and IV Hodgkin's disease were prospectively randomized to receive either treatment with the methanol extraction residue of Bacillus Calmette-Guerin (MER/BCG) or no immunotherapy. Prior to the MER/BCG randomization, patients received six courses of induction and two years of maintenance chemotherapy so that a group with a presumptively low tumor burden could be established. Only patients achieving a complete remission were evaluated. During the first two years of immunotherapy, the MER/BCG group had a relapse frequency twice that of controls. The overall crude relapse frequency and disease-free survival were similar between the two treatment groups. The MER/BCG dose schedule used in this study was associated with a high frequency of unacceptable toxicity. Ulcerations of greater than 1 cm occurred in one-third of the patients with associated pain, fever, and occasional lymphadenopathy. A high degree of patient noncompliance (36%) was observed. Age (P = 0.002), prior radiotherapy (P = 0.032), and chemotherapy (P = 0.044) were prognostic factors found to significantly influence remission duration. These factors were balanced between patients treated with immunotherapy and those who were not. MER/BCG therapy did not significantly delay or prevent relapse.

Adult↗